Cost of Illness of Multiple Sclerosis in Isfahan, Iran, From a Social Perspective: A Comparison of the Human-Capital and Friction-Cost Methods

Amirsadri, Mohammadreza; Rahimi, Farimah; Khajepour, Azin

doi:10.1016/j.vhri.2021.10.006

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major complications of diabetes evaluated in the current study included blindness, end-stage renal disease (ESRD), myocardial infarction (MI), stroke, lower extremity amputation (LEA), and death. The results are reported with no discount, a discount rate of 3% for both costs and effects (based on the recommendations of the WHO-choice)( 8 ), as well as a scenario with a discount rate of 7.2% for costs (according to a domestic study) and 3% for effects( 9 10 ). The main measured consequences were life-years-gained (LYG) and quality-adjusted-life-year (QALY).…”

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran

Amirsadri

Torkpour²

2023

Res Pharma Sci

View full text Add to dashboard Cite

Background and purpose: Several studies have shown the effectiveness of screening programs in decreasing the costs and disutility of type-2 diabetes and related complications. As there is a growth in the incidence of type-2 diabetes amongst the Iranian population, the cost-effectiveness of performing type-2 diabetes screening tests in community pharmacies of Iran was evaluated in this study from the payer’s perspective. The target population consisted of two hypothetical cohorts of 1000 people 40 years of age without a prior diagnosis of diabetes, for the intervention (screening test) and no-screening groups. Experimental approach: A Markov model was developed to evaluate the cost-effectiveness and cost-utility of a type-2 diabetes screening test in community pharmacies in Iran. A 30-year time horizon was considered in the model. Three screening programs with 5-year intervals were considered for the intervention group. The evaluated outcomes were quality-adjusted life-years (QALYs) for cost-utility-analysis and life-years-gained (LYG) for cost-effectiveness-analysis. To examine the robustness of the results, one-way and probabilistic-sensitivity analyses were applied to the model. Findings/Results: The screening test represented both more effects and higher costs. The incremental effects in the base-case scenario (no-discounting) were estimated to be 0.017 and 0.0004 (approximately 0) for QALYs and LYG, respectively. The incremental cost was estimated to be 2.87 USD/patient. The estimated incremental-cost-effectiveness ratio was 164.77 USD/QALY. Conclusion and implications: This study indicated that screening for type-2 diabetes in community pharmacies of Iran could be considered highly cost-effective, as it meets the WHO criteria of the annual GDP per capita ($2757 in 2020).

show abstract

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran

Amirsadri

Torkpour²

2023

Res Pharma Sci

View full text Add to dashboard Cite

show abstract

“…19 There is evidence of rising MS prevalence and incidence in Iran. 20 , 21 The cost of MS was estimated to be $238 124 160 in 2019-2020, 22 or about US$ 34000 per patient 23 which seems a notable number for Iran’s level of income. This high economic burden, in addition to international sanctions, could limit the patients’ access to treatments.…”

Section: Introductionmentioning

confidence: 99%

Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis

Ghadiri,

Sahraian,

Ashtari

et al. 2023

Arch Iran Med

View full text Add to dashboard Cite

Background: Multiple sclerosis (MS) may be affected by socioeconomic status (SES). This study aims to explore the determinants of SES among Iranian patients with MS and examine how these factors relate to disability and disease progression. Methods: All patients with MS listed in the nationwide MS registry of Iran (NMSRI) until January 8, 2022, were included in this population-based study. Results: Among the 5153 patients, most were female (74.5%), married (70.8%), and did not hold an academic degree (53.8%). Unemployment (OR: 3.75) and being unmarried (OR: 2.60) were significantly associated with Expanded Disability Status Scale (EDSS)≥6, and the time to progression was shorter in the unemployed group (P value: 0.03). There was also a significant negative correlation between the time to progression and the age at disease onset. Conclusion: The study suggests that providing financial and social support to MS patients and their families through investment could reduce both individual and societal burdens.

show abstract

The cost-of-illness of multiple sclerosis in Jordan

Alabbadi,

Al-Ajlouny,

Alsoud

et al. 2024

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Cost of Illness of Multiple Sclerosis in Isfahan, Iran, From a Social Perspective: A Comparison of the Human-Capital and Friction-Cost Methods

Cited by 3 publications

References 25 publications

Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran

Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran

Economic and Social Standing of Individuals in Iran Diagnosed with Multiple Sclerosis

The cost-of-illness of multiple sclerosis in Jordan

Contact Info

Product

Resources

About